


EMA-EUnetHTA Parallel Consultation

Current State, AMS Expertise & Services

One Data Package to Meet Different Requirements





Requirements for HTA may differ across Member States based on national and regional legislation

Marketing Authorisation vs. HTA – Two Different Questions



Marketing authorisation (MA)/ Clinical studies HTA/ Evidence based medicine (EbM)

Does it work?

- Efficacy: "Yes or No"-decision based on prospective studies
- Proof of efficacy based on a formal confirmatory test
- Focus on primary endpoint, secondary endpoints exploratory/supportive

→Approval based on a positive benefit-risk balance Is it better?

- Relative **Effectiveness**: **Retrospective** analysis of existing study data
- Description of existing evidence: Effect size and reliability of the recommendation
- Patient relevance is key: No differentiation between primary and secondary endpoints
 - →Added value based on clinical evidence

EMA-EUnetHTA Parallel Consultation



Enhanced collaboration between EMA and EUnetHTA: A single gateway for requests for parallel discussions (since 07/2017)

- For Initial Evidence Generation: Before start of pivotal clinical trials
- For Post Licensing Evidence Generation (PLEG)
- Simultaneous advice from EMA and HTA bodies (HTABs)
- Objective: To help generate optimal and robust evidence in an efficient development plan that satisfies the needs of both regulators and HTABs

Parallel Consultation – Benefits of the platform






- Structured interaction between EMA & HTABs one contact point for the applicant, common briefing document
- Improved coordination and central recruitment of HTABs by EUnetHTA ED Secretariat
- Streamlined procedure based on the EMA`s Scientific Advice timetables
- Stable group of HTABs with significant experience in EDs (EDWP)
- Inclusion of patient representatives and healthcare professionals on a routine basis

One Procedure – Two Pathways






Parallel Consultation Process



Simultaneous notification of EMA Scientific Advice Secretariat and EUnetHTA ED Secretariat



Reference: Guidance for Parallel Consultation: https://eunethta.eu/wp-content/uploads/2018/03/Guidance-on-Parallel-Consultation.pdf


Parallel EMA/HTAB Advice




Simultaneous feedback from Regulators and HTA Bodies: Your Benefits

- Understand different data requirements, alignment or divergence
- Optimize your evidence generation plans
- Manage and align expectations with internal and external stakeholders at an early stage

Why AMS?





Medical Writing

- ✓ Effective biomedical writing, clear focus on essentials
- ✓ Providing the appropriate level of detail, striking the right tone for each target group

Biostatistics

- ✓ Basic and advanced statistical analyses
- ✓ Strategic consulting, reliable programming and attractive reporting

Practical Expertise

- ✓ Numerous Scientific Advice procedures
- ✓ Requirements and mindset of authorities

Experts

 ✓ In-depth knowledge of legislative and regulative requirements

AMS Advanced Medical Ser

✓ Medical consulting

Flexibility

✓ Very flexible to manage projects on short notice

Close Cooperation

 ✓ With industry associations, e.g. presentations at VfA, BPI, EUCOPE, EFPIA

Constantly up-to-date


 ✓ With recent developments regarding European HTA

Continous Exchange

✓ With national HTA bodies and EUnetHTA

Future Situation in Europe





- ✓ Stronger European voice in global clinical development
- ✓ Better business predictability

Interested in Learning More?





